<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An intravital microscopy imaging method was developed to visualize active <z:e sem="disease" ids="C0936263" disease_type="Disease or Syndrome" abbrv="">cerebral thrombus</z:e> and blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) disruption using Near Infrared Fluorescent (NIRF) probes </plain></SENT>
<SENT sid="1" pm="."><plain>A circular craniotomy was made in CD-1 mice </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e> were formed by applying 10%-<z:chebi fb="0" ids="30808">FeCl3</z:chebi> to the entire exposed superior sagittal sinus (SSS, 5 mm), or to the posterior 2.5 mm of the SSS for 5 mins </plain></SENT>
<SENT sid="3" pm="."><plain>Control animals were pretreated with <z:chebi fb="5" ids="28304">heparin</z:chebi> (50 U/kg) before <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> induction </plain></SENT>
<SENT sid="4" pm="."><plain>Three hours after <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, a FXIIIa-targeted NIRF imaging probe (A15) was intravenously injected, and the SSS was imaged by intravital microscopy </plain></SENT>
<SENT sid="5" pm="."><plain>This was followed by injection of <z:chebi fb="0" ids="31696">indocyanine green</z:chebi> (ICG) to assess <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability </plain></SENT>
<SENT sid="6" pm="."><plain>The A15 optical probe bound to <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, and the fluorescent signal emitted by the bound agent corresponded well with histologically confirmed <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>A15 initially remained intravascular, followed by excretion and subsequent decrease in <z:hpo ids='HP_0000001'>all</z:hpo> tissues except for <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, where it was retained </plain></SENT>
<SENT sid="8" pm="."><plain>The subsequent ICG was also intravascular immediately after injection, but then began to leak into the cerebral parenchyma at 3 to 5 mins </plain></SENT>
<SENT sid="9" pm="."><plain>The sites of leakage were adjacent to thrombosed areas </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> pretreatment prevented <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and reduced ICG leakage significantly </plain></SENT>
<SENT sid="11" pm="."><plain>This demonstrates the feasibility of simultaneous in vivo monitoring of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> and <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability in an animal model of <z:hpo ids='HP_0005305'>cerebral venous thrombosis</z:hpo> </plain></SENT>
</text></document>